BioMerieux (BioMerieux) Research & Development : $500 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BioMerieux's Research & Development for the six months ended in Dec. 2023 was $255 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $500 Mil.

BioMerieux Research & Development Historical Data

The historical data trend for BioMerieux's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Research & Development Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

415.89

485.16

435.93

473.09

501.75

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															231.41	219.13	253.50	245.40	254.74

BioMerieux Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $500 Mil.

BioMerieux (OTCPK:BMXMF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioMerieux Research & Development Related Terms

Thank you for viewing the detailed overview of BioMerieux's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux (BioMerieux) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

BIMp:UK 0RUG:UK BIM:France EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (BioMerieux) Headlines

From GuruFocus

French multidisciplinary consortium ARPEGE awarded public funding of close to �9 million to fight antibiotic resistance

By PRNewswire PRNewswire • 01-06-2022

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire • 02-02-2023